Seoul Doctors Boost Crohn's Fistula Cure Rate to 83%

Researchers in Seoul just gave hope to millions of Crohn's disease patients struggling with one of the condition's most painful complications.

Doctors at Asan Medical Center discovered that injecting a salmon-derived DNA fragment called PDRN during fistula surgery increased the cure rate to 83.3%, compared to just 46.2% with surgery alone. That's nearly double the success rate.

The results get even better. Patients who received PDRN healed in an average of 3.3 months, slashing recovery time by 2.6 months compared to standard surgery.

For the 3 million people worldwide living with Crohn's disease, anal fistulas represent one of the most challenging complications. These painful tunnel-like passages form between the intestine and skin, causing chronic discomfort and serious infections.

Until now, stem cell therapy offered the best results at around 70% effectiveness. But the treatment remains out of reach for most patients due to costs exceeding $10,000 and complex cell-culturing requirements.

PDRN changes that equation entirely. The purified DNA fragment extracted from salmon sperm costs roughly 1% of stem cell therapy and requires no special preparation.

Professors Yoon Yong-sik and Lee Jong-lyul led the research team that developed a standardized injection technique. They tested it on 47 patients between 2018 and 2024, carefully comparing outcomes between those who received PDRN and those who didn't.

The treatment works by promoting cell regeneration and reducing inflammation. Because PDRN's structure closely resembles human DNA, patients experience very few adverse reactions.

Why This Inspires

This breakthrough matters because it solves two problems at once: better results and better access.

The near-doubling of cure rates means fewer repeat surgeries and less suffering for patients already managing a difficult chronic disease. Faster healing gets people back to normal life months sooner.

But the affordability factor might be even more important. When a treatment costs 99% less than the current best option, it stops being a luxury and becomes genuinely available to people who need it most.

PDRN is already proven safe through years of use in wound healing, joint treatments, and skin regeneration. Now doctors can simply add it to existing surgical procedures without special equipment or training.

The research appeared in Inflammatory Bowel Diseases, a top journal in the field. Professor Yoon believes PDRN could be administered not just during surgery but even in outpatient settings, making treatment more convenient while reducing financial burden.

For Crohn's patients facing fistula complications, this represents the kind of medical advance that changes daily life, not just medical charts.